Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

被引：13

作者：

Browning, Rebekah L. ^{[1
]}

Geyer, Susan M. ^{[2
]}

Johnson, Amy J. ^{[1
]}

Jelinek, Diane E. ^{[2
]}

Tschumper, Renee C. ^{[2
]}

Call, Timothy G. ^{[2
]}

Shanafelt, Tait D. ^{[2
]}

Zent, Clive S. ^{[2
]}

Bone, Nancy D. ^{[2
]}

Dewald, Gordon W. ^{[2
]}

Lin, Thomas S. ^{[1
]}

Heerema, Nyla A. ^{[1
]}

Grever, Michael R. ^{[1
]}

Kay, Neil E. ^{[2
]}

Byrd, John C. ^{[1
]}

Lucas, David M. ^{[1
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Mayo Clin, Rochester, MN USA

来源：

LEUKEMIA RESEARCH | 2007年 / 31卷 / 12期

关键词：

chronic lymphocytic leukemia (CLL); TCL-1; prognostic factor; Pentostatin; chemoimmunotherapy;

D O I：

10.1016/j.leukres.2007.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p = 0.046). Trends toward improved complete remission rate (49% versus 19%, p = 0.064) and progression-free survival (medians: 33 versus 20 months, p = 0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted. Published by Elsevier Ltd.

引用

页码：1737 / 1740

页数：4

共 50 条

[41] The prognostic significance of immunoglobulin gene rearrangements in B-cell chronic lymphocytic leukemia
Brown, PN
Jurlander, J
Geisler, C
Hansen, MM
Drivsholm, A
BLOOD, 1995, 86 (10) : 2993 - 2993
[42] Definition and validation of novel prognostic markers in B-CELL chronic lymphocytic leukemia
Kotaskova, J.
Tichy, B.
Malcikova, J.
Kuhrova, V.
Doubek, M.
Brychtova, Y.
Borsky, M.
Dvorakova, D.
Mayer, J.
Pospisilova, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 390 - 390
[43] Alemtuzumab for B-cell chronic lymphocytic leukemia
Robak, Tadeusz
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1033 - 1051
[44] Rituximab in B-cell chronic lymphocytic leukemia
Lin, TS
Lucas, MS
Byrd, JC
SEMINARS IN ONCOLOGY, 2003, 30 (04) : 483 - 492
[45] Alemtuzumab in B-cell chronic lymphocytic leukemia
Shapira, I
Grossbard, ML
CLINICAL LYMPHOMA, 2004, 4 (04): : 228 - 229
[46] Histopathology of B-cell chronic lymphocytic leukemia
Pileri, SA
Sabattini, E
Agostinelli, C
Bodega, L
Rossi, M
Zinzani, PL
Marafioti, T
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (04) : 807 - +
[47] The origin of B-cell chronic lymphocytic leukemia
Ghia, P
Caligaris-Cappio, F
SEMINARS IN ONCOLOGY, 2006, 33 (02) : 150 - 156
[48] The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy
Packham, Graham
Krysov, Serge
Allen, Alex
Savelyeva, Natalia
Steele, Andrew J.
Forconi, Francesco
Stevenson, Freda K.
HAEMATOLOGICA, 2014, 99 (07) : 1138 - 1148
[49] Mevalonate pathway inhibitors in the treatment of B-cell chronic lymphocytic leukemia
Bobba, Ravi Kiran
Benakanakere, Indira
Bearelly, Smitha
Arya, Monica
Sleigtholm, Richard
Freter, Carl
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[50] ADVANCES IN THE BIOLOGY AND TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA
OBRIEN, S
DELGIGLIO, A
KEATING, M
BLOOD, 1995, 85 (02) : 307 - 318

← 1 2 3 4 5 →